BRAF V600 Mutation Analysis

Function

The BRAF gene provides instructions for making a protein that helps transmit chemical signals from outside the cell to the cell's nucleus. This protein is part of the RAS/MAPK pathway, which controls cell growth, proliferation, and differentiation. The V600 mutation (most commonly V600E) causes the BRAF protein to be permanently 'turned on,' leading to uncontrolled cell division and tumor growth.

Why it is Ordered

This test is primarily ordered for patients diagnosed with specific types of cancer, most notably metastatic melanoma, colorectal cancer, papillary thyroid carcinoma, and non-small cell lung cancer (NSCLC). Identifying a BRAF mutation is crucial for determining eligibility for targeted therapies. For instance, melanoma patients with a V600E or V600K mutation can be treated with BRAF inhibitors (like vemurafenib or dabrafenib) often in combination with MEK inhibitors. In colorectal cancer, the mutation is also a significant prognostic marker.

Associated Conditions

• Metastatic Melanoma: Approximately 50% of melanomas harbor a BRAF mutation.
• Colorectal Cancer: Associated with a poorer prognosis but helps in deciding against certain EGFR-inhibitor therapies.
• Papillary Thyroid Carcinoma: Associated with more aggressive tumor behavior.
• Erdheim-Chester Disease: A rare blood cancer frequently linked to BRAF mutations.

Identifying these mutations allows for 'precision medicine,' where treatment is tailored to the genetic profile of the tumor rather than a one-size-fits-all approach.